• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/9/21 3:52:53 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORMP alert in real time by email
    SC 13G/A 1 ea135034-sc13gaslager_oramed.htm AMENDMENT TO FORM SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    ORAMED PHARMACEUTICALS INC.

    (Name of Issuer)

     

    Common Stock, par value $0.012 per share

    (Title of Class of Securities)

     

    68403P203

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 2 of 10 Pages

     

    1.

    Names of Reporting Persons

    Regals Capital Management LP

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    1,344,123

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    1,344,123

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,344,123

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.04%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 3 of 10 Pages

     

    1.

    Names of Reporting Persons

    Regals Fund LP

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    1,344,123

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    1,344,123

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,344,123

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

     

    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.04%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 4 of 10 Pages

     

    1.

    Names of Reporting Persons

    David M. Slager

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Netherlands

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    1,344,123

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    1,344,123

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,344,123

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.04%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 5 of 10 Pages

     

    This Amendment No. 1 is filed with respect to shares of Common Stock (as defined below) of Oramed Pharmaceuticals, Inc. beneficially owned by the Reporting Persons (as defined below) as of December 31, 2020, and amends and reinstates the Schedule 13G filed by the Reporting Persons on February 11, 2020.

     

    Item 1(a).Name of Issuer

     

    Oramed Pharmaceuticals Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices

     

    1185 Avenue of the Americas, Suite 228, New York, NY 10036.

     

    Item 2(a).Name of Person Filing

     

    This Schedule is filed on behalf of each of the following Reporting Persons:

     

    (1) Regals Capital Management LP (“Regals Management”)

     

    (2) Regals Fund LP (“Regals Fund”)

     

    (3) David M. Slager (“Mr. Slager”)

     

    Item 2(b).Address of Principal Business Offices or, if None, Residence

     

    The address of each Reporting Person is:

     

    c/o Regals Capital Management LP
    152 West 57th Street, 9th Floor
    New York, NY 10019

     

    Item 2(c).Citizenship

     

    Each of Regals Management and Regals Fund is a Delaware limited partnership.

     

    Mr. Slager is a citizen of The Netherlands.

     

    Item 2(d).Title of Class of Securities

     

    Common Stock.

     

    Item 2(e).CUSIP Number

     

    68403P203

     

    Item 3.If the statement is being filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the filing person is a:

     

    Not Applicable

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 6 of 10 Pages

     

    Item 4.Ownership

     

    (a) Amount beneficially owned:

     

    Each Reporting Person may be deemed to beneficially own 1,344,123 shares of Common Stock of the Issuer, including 20,000 shares underlying currently exercisable shares. Regals Management is the investment manager of Regals Fund, the owner of record of the Common Stock reported in this Schedule. Mr. Slager is the managing member of the general partner of Regals Management. All investment decisions are made by Mr. Slager, and thus the power to vote or direct the votes of these shares of Common Stock, as well as the power to dispose or direct the disposition of such shares of common stock is held by Slager through Regals Management.

     

    (b) Percent of class:

     

    Each Reporting Person may be deemed to beneficially own 5.04% of the outstanding shares of Common Stock of the Issuer based upon 26,661,004 shares of Common Stock issued and outstanding as of January 14, 2021, as reported in Issuer’s Quarterly Report form 10-Q, filed with the Securities and Exchange Commission on January 14, 2021.

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

     

    Regals Management:   0 
    Regals Fund:   0 
    Mr. Slager:   0 

     

    (ii) Shared power to vote or to direct the vote:

     

    Regals Management:   1,344,123 
    Regals Fund:   1,344,123 
    Mr. Slager:   1,344,123 

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    Regals Management:   0 
    Regals Fund:   0 
    Mr. Slager:   0 

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    Regals Management:   1,344,123 
    Regals Fund:   1,344,123 
    Mr. Slager:   1,344,123 

     

    Reference is made to Item 4(a) above as to the Issuer’s Common Stock that may be deemed to be beneficially owned by the Reporting Persons.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not Applicable

     

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 7 of 10 Pages

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10.Certification

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 8 of 10 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each Reporting Person certifies that the information set forth in this statement is true, complete and correct.

     

    Dated:  February 9, 2021 Regals Capital Management LP
      By: Regals Capital Holdings LLC, its general partner
       
      /s/ David M. Slager
      Name: David M. Slager
      Title: Managing Member
       
    Dated:  February 9, 2021 Regals Fund LP
      By: Regals Fund GP LLC, its general partner
       
      /s/ David M. Slager
      Name: David M. Slager
      Title: Managing Member
       
    Dated:  February 9, 2021 David M. Slager
       
      /s/ David M. Slager
      Name: David M. Slager

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

      

     

     

     

    CUSIP No. 68403P203 13G/A Page 9 of 10 Pages

     

    EXHIBIT INDEX

     

    Exhibit   Description
         
    99.1   Agreement of Joint Filing. (Filed herewith)

     

     

    Get the next $ORMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORMP

    DatePrice TargetRatingAnalyst
    1/12/2023$30.00 → $3.00Buy → Hold
    Canaccord Genuity
    2/18/2022$20.00Overweight
    Cantor Fitzgerald
    11/30/2021$17.00 → $32.00Buy
    HC Wainwright & Co.
    11/29/2021$17.00 → $32.00Buy
    HC Wainwright & Co.
    11/2/2021$20.00 → $35.00Buy
    Aegis Capital
    7/29/2021$27.00 → $30.00Buy
    Canaccord Genuity
    More analyst ratings

    $ORMP
    SEC Filings

    See more
    • Oramed Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

      8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

      5/21/25 4:05:14 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Oramed Pharmaceuticals Inc.

      10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

      5/15/25 4:06:38 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oramed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

      4/28/25 4:30:31 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oramed Pharmaceuticals downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously

      1/12/23 7:54:45 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Oramed Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of Oramed Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

      2/18/22 6:43:35 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Oramed Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $17.00 previously

      11/30/21 7:36:11 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mayer Arie was granted 36,975 shares, increasing direct ownership by 38% to 133,109 units (SEC Form 4)

      4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

      6/9/25 4:08:35 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Aghion Daniel was granted 38,371 shares, increasing direct ownership by 99% to 77,191 units (SEC Form 4)

      4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

      6/9/25 4:08:22 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Reznick Yehuda was granted 38,370 shares, increasing direct ownership by 126% to 68,930 units (SEC Form 4)

      4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

      6/9/25 4:08:06 PM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORMP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical

      Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK, April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (NASDAQ:ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that

      4/28/25 9:00:00 AM ET
      $DRTS
      $ORMP
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals

      JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the "offering") whereby an affiliate of Oramed Pharmaceuticals Inc. ("Oramed") (NASDAQ:ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. The offering closed on April 28, 2025.   The total gross proceeds of the offering were approximately $36.9 million, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau int

      4/28/25 9:00:00 AM ET
      $DRTS
      $ORMP
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Oramed Pharmaceuticals Issues Letter to Shareholders

      Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials.Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing.Cash dividend planned (~$0.25 per share).Marketing Authorization Application has been submitted by HTIT, and commercialization preparations are underway for oral insulin capsule. OraTech expected to receive royalties from sales in China.Oramed to receive royalty streams over the next decade from multiple Scilex products including $400,000 due for Q4 2024 sales.NEW YORK, March 4, 2025 /

      3/4/25 9:00:00 AM ET
      $ORMP
      Biotechnology: Pharmaceutical Preparations
      Health Care